The estimated Net Worth of Jon W Salveson is at least $811 Tysiąc dollars as of 7 June 2012. Mr. Salveson owns over 25,000 units of Artivion Inc stock worth over $625,800 and over the last 18 years he sold CRY stock worth over $0. In addition, he makes $185,015 as Independent Director at Artivion Inc.
Sign up
Mr. Salveson CRY stock SEC Form 4 insiders trading
Jon has made over 1 trades of the Artivion Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of CRY stock worth $119,750 on 7 June 2012.
The largest trade he's ever made was buying 25,000 units of Artivion Inc stock on 7 June 2012 worth over $119,750. On average, Jon trades about 1,042 units every 0 days since 2007. As of 7 June 2012 he still owns at least 35,000 units of Artivion Inc stock.
You can see the complete history of Mr. Salveson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jon Salveson biography
Jon W. Salveson is Independent Director of the Company. He has served as a director of CryoLife since May 2012. Mr. Salveson is the Vice Chairman, Investment Banking and Chairman of the Healthcare Investment Banking Group at Piper Sandler Companies (NYSE: PIPR) (“Piper Sandler”), formerly Piper Jaffray Companies, a U.S. investment bank and asset management firm. Mr. Salveson has served in his present position as Vice Chairman, Investment Banking since July 2010. Mr. Salveson was appointed Global Head of Investment Banking and a member of the Executive Committee of Piper Jaffray in 2004. He joined Piper Jaffray in 1993 as an associate, was elected Managing Director in 1999, and was named the Group Head of Piper Jaffray’s international healthcare investment banking group in 2001. Mr. Salveson also serves on the Board of Directors of CHF Solutions, Inc. (NASDAQ: CHFS), an early-stage medical device company, and Asklepios Biopharmaceuticals, Inc., a private company specializing in gene therapy technologies. Mr. Salveson received his undergraduate degree from St. Olaf College in 1987 and an M.M.M. in finance from the Kellogg Graduate School of Management at Northwestern University.
What is the salary of Jon Salveson?
As the Independent Director of Artivion Inc, the total compensation of Jon Salveson at Artivion Inc is $185,015. There are 14 executives at Artivion Inc getting paid more, with James Mackin having the highest compensation of $6,453,540.
How old is Jon Salveson?
Jon Salveson is 55, he's been the Independent Director of Artivion Inc since 2012. There are 11 older and 10 younger executives at Artivion Inc. The oldest executive at Artivion Inc is Ronald McCall, 83, who is the Presiding Independent Director.
Insiders trading at Artivion Inc
Over the last 21 years, insiders at Artivion Inc have traded over $18,346,910 worth of Artivion Inc stock and bought 91,700 units worth $1,086,548 . The most active insiders traders include Steven G Anderson, Thomas F Ackerman oraz James P Mackin. On average, Artivion Inc executives and independent directors trade stock every 26 days with the average trade being worth of $211,842. The most recent stock trade was executed by Amy Horton on 8 December 2021, trading 2,500 units of CRY stock currently worth $46,425.
What does Artivion Inc do?
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.
What does Artivion Inc's logo look like?
Complete history of Mr. Salveson stock trades at CHF Solutions Inc i Artivion Inc
Artivion Inc executives and stock owners
Artivion Inc executives and other stock owners filed with the SEC include:
-
James Mackin,
Chairman of the Board, President, Chief Executive Officer, Director -
D. Ashley Lee,
Chief Financial Officer, Chief Operating Officer, Executive Vice President -
Jean Holloway,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Michael Simpson,
Senior Vice President - Regulatory Affairs and Quality Assurance -
John Davis,
Senior Vice President - Global Sales and Marketing -
James Patrick Mackin,
Chairman, Pres & CEO -
Scott Capps,
Vice President - Clinical Research -
David Ashley Lee CPA, CPA,
Exec. VP, COO & CFO -
Jean F. Holloway Esq.,
Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
John E. Davis,
Sr. VP of Global Sales & Marketing -
Harvey Morgan,
Independent Director -
Daniel Bevevino,
Independent Director -
Ronald McCall,
Presiding Independent Director -
Thomas Ackerman,
Independent Director -
Jon Salveson,
Independent Director -
James Bullock,
Independent Director -
Jeffrey Burbank,
Independent Director -
Marna Borgstrom,
Independent Director -
Greg Chodaczek,
IR Contact Officer -
Matthew Getz,
Vice President - Human Resources -
Dennis Maier,
Vice President - Operations -
Amy Horton,
Chief Accounting Officer, Vice President -
Thomas Bogenschutz,
Senior Vice President - EMEA, General Manager - Hechingen -
Dr. Marshall S. Stanton,
Sr. VP of Clinical Research & Chief Medical Officer -
Joshua Wells,
Sr. Director of Bus. Devel. -
Matthew A. Getz,
VP of HR -
Amy D. Horton CPA, CPA,
VP & Chief Accounting Officer -
Sherry M Saurini,
VP, Quality -
C Elkins Ronald,
Director -
James Benson,
Director -
James M Mc Dermid,
SVP, CHRO -
David C Gale,
VP-Research and Development -
William Robert Matthews,
Senior VP, Operations, Quality -
Thomas J Bogenschuetz,
VP, EMEA & General Manager -
Bruce G. Anderson,
VP, US Sales and Marketing -
Jeffrey W Burris,
Vice President & Gen. Counsel -
Gerald B Seery,
Sr. VP, Sales and Marketing -
John M Cook,
Director -
David P. Lang,
Sr. VP, Intl Sales & Marketing -
Steven G Anderson,
President, CEO and Chairman -
Thomas J Lynch,
VP - Reg. Aff./Quality Assur. -
Capital Management Oss,
10% owner -
Philip A Theodore,
VP, General Counsel -
Michaelstark Brian Jay Roth,
-
Sidney B Ashmore,
Vice President of Marketing -
Virginia C Lacy,
Director -
Dyne Bruce J Md Van,
Director -
Albert E Heacox,
Sr. VP-Laboratory Operations -
Vander James C Wyk,
VP - Product Integrity -
Kirby S Black,
Sr. Vice President, R&D -
David Fronk,
VP - Clinical Research -
Rochelle L. Maney,
VP, Quality -
Franz Peter Barthold,
VP, Research & Development -
Marshall S. Stanton,
SVP, Clinical & MD Affair -
Anthony B. Semedo,
Director